MRK Company Profile and Key Details

Q: Who are the executives of MRK?

Lisa LeCointe-CephasSenior Vice President and Chief Ethics & Compliance OfficerMr. Kenneth C. FrazierExecutive ChairmanMs. Cristal N. DowningExecutive Vice President and Chief Communications & Public Affairs OfficerMs. Caroline LitchfieldExecutive Vice President & Chief Financial OfficerMs. Jennifer L. ZacharyExecutive Vice President & Gen. CounselMr. Richard R. DeLuca Jr.Executive Vice President & Pres of Merck Animal HealthMr. Robert M. Davis J.D.Chairman, Pres & Chief Executive OfficerMr. Peter DannenbaumVice President of Investor RelationsMr. Steven C. MizellExecutive Vice President & Chief HR OfficerMr. Chirfi GuindoSenior Vice President & Chief Marketing Officer for Merck Human HealthMr. David Michael WilliamsExecutive Vice President and Chief Information & Digital OfficerDr. Dean Y. Li M.D., Ph.D.Executive Vice President & Pres of Merck Research LaboratoriesMs. Jennifer MauerHead of Global Communications & Corporation Brand

NYSE : MRK

Merck & Co

$105.08

0.36+0.34%

Open: 3:52 PM

74.61

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Merck & Co., Inc. (MRK) stock surged +0.34%, trading at $105.08 on NYSE, up from the previous close of $104.72. The stock opened at $104.56, fluctuating between $104.33 and $105.39 in the recent session.

Stock Snapshot

104.72

Prev. Close

264.09B

Market Cap

104.325

Day Low

13.9

P/E Ratio

7.56

EPS (TTM)

3.61

Cash Flow per Share

104.56

Open

2.51B

Number of Shares

105.3899

Day High

99.84%

Free Float in %

14.84

Book Value

9.58M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 22, 2025	100.63	104.95	100.40	104.72	16.9M
Dec 19, 2025	100.60	102.20	100.11	101.09	42.87M
Dec 17, 2025	98.18	100.14	98.06	99.18	13.18M
Dec 16, 2025	100.30	100.34	96.79	98.27	16.66M
Dec 15, 2025	99.99	100.94	98.00	100.26	16.43M
Dec 12, 2025	98.96	100.66	98.32	100.30	11.76M
Dec 11, 2025	98.44	99.14	97.58	99.01	11.65M
Dec 10, 2025	98.05	98.17	96.47	97.62	17.52M
Dec 09, 2025	99.32	99.85	96.06	96.89	15.22M
Dec 08, 2025	99.38	99.67	97.81	98.93	12.68M
Dec 05, 2025	102.10	102.10	99.19	99.72	10.38M
Dec 04, 2025	102.10	102.60	100.54	100.89	12.72M
Dec 03, 2025	101.89	103.09	101.52	102.27	7.83M
Dec 02, 2025	101.53	101.80	100.31	101.03	9.1M
Dec 01, 2025	104.72	105.68	101.71	101.83	14.17M
Nov 28, 2025	104.84	105.41	104.12	104.83	6.15M
Nov 26, 2025	104.60	105.75	104.20	104.63	12.27M
Nov 25, 2025	100.73	105.84	100.71	105.66	21.91M
Nov 24, 2025	99.12	102.36	99.12	100.40	27.75M
Nov 21, 2025	95.48	100.27	95.36	97.76	23.04M

Contact Details

Rahway, NJ 07033

United States

https://www.merck.com 908 740 4000

About Company

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Stock Peers

LLY

5.04+0.47%

Eli Lilly and Company$1,076.48 ABBV

1.09+0.48%

AbbVie Inc.$227.91 JNJ

0.95+0.46%

Johnson & Johnson$207.32 NVS

0.81+0.60%

Novartis AG$136.87 BMY

0.465+0.86%

Bristol-Myers Squibb Company$54.66 GSK

-0.02-0.04%

GSK plc$48.59 NVO

0.01+0.02%

Novo Nordisk A/S$48.10 PFE

0.02+0.08%

Pfizer Inc.$25.21 OGN

0.15+2.20%

Organon & Co.$6.98 SRXH

-0.014-4.49%

SRx Health Solutions Inc.$0.30

Company Overview

Merck & Co., Inc. (NYSE:MRK) closed at $105.08 USD, gaining $0.36 (0.34%) from the previous close of $104.72. The stock is currently trading near its 52-week high $73.31 and $105.84. With a market capitalization of about $264.09 billion, Merck & Co., Inc. is classified as a mega-cap and shows lower-than-market volatility (beta ~0.30). Key stats such as the average daily volume over the past year has been around 14.10 million shares, volume is running light vs its 52-week average. Headquartered in Rahway, NJ, Merck & Co., Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Robert Davis, the company employs approximately 73,000 people and listed since January 13, 1978. Merck & Co., Inc. operates as a healthcare company worldwide.

Technical Performance

MRK has shown sold momentum, gaining 4.41% over the past week and 30.25% over the past quarter, though year-to-date performance is up 5.27%. Short-term trend indicators are bearishly aligned (SMA20 3.77%, SMA50 12.21%, SMA200 22.84%). The stock’s 14-day RSI is 67.42 (firm momentum), while the ATR of 2.72 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -1.06% below its high and over 42.85% above its low. Average 10-day trading volume of 21.21 million shares is significantly above the 3-month average of 13.53 million, indicating heightened recent market interest.

Valuation Metrics

Merck & Co., Inc. trades at a P/E ratio of 13.7, slightly below the S&P 500 average, with a price-to-sales ratio of 4.08 and a price-to-book ratio of 5.03 trading at moderately above to book value. The P/FCF stands at 20.11, also above market averages.

Dividend & Fair Value

Merck & Co., Inc. last paid a dividend of 3.28 per share, this equals a trailing yield of roughly 2.38%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $275.26. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Merck & Co., Inc. generated EPS of $7.56 over the past year. Five-year average earnings growth is 12.04%. Wall Street analysts project EPS growth of 10.02% annually over the next five years. The latest quarter delivered EPS of $2.58. The next quarter is forecast at $2.05. Next year's EPS is expected at $454.63. Analyst sentiment is neutral. Analyst rating data shows there are 4 Strong Buy ratings, 7 Buy ratings, 12 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $130.00 to $90.00. The high target offers 24.14% upside. The low target suggests -14.06% downside. The mean target is $110.30. This offers 5.33% upside. Merck & Co., Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by 9.32%. The prior quarter beat by 4.93%. Over the last six quarters, Apple has recorded several small beats. These include 5.56% in July 30, 2024.

Shareholding & Insider Activity

Merck & Co., Inc. has 2.50 billion shares outstanding. The public float is 2.49 billion shares, elevated short interest at 1.15% of float. This equals 25.88 million shares. The short ratio is 1.92 days. Institutional investors hold 80.64% of the float. Insiders own 0.07%. FRAZIER KENNETH C holds 700.65 thousand shares, Davis Robert M has 348.33 thousand shares and DeLuca Richard R. has 111.76 thousand shares. Over the past six months, insider transactions show net selling. They sold 15.70 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Merck & Co generated $59.87B in revenue, or $23.51 per share. Gross margin was 73.31%, operating margin 4.98%, and net profit margin 0.61%. Returns are modest, with ROA at 0.34% and ROE at 0.97%.
On valuation metrics, Merck & Co trades at a P/E of 13.70, P/S of 4.08 and P/B of 5.03. The current ratio is 1.66 and quick ratio is 1.44. Operationally, the company’s inventory turnover is 2.16 and cash conversion cycle is 129.06 days. Debt-to-equity is 0.80, supported by a cash flow-to-debt ratio of 0.41.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Merck & Co posted revenue of $59.87B, down slightly from $59.28B in the prior quarter. Gross profit was $43.89B (margin 73.31%). Operating income was $2.98B (margin 5.0%). Net income was$365.00M (EPS $0.14).
The company ended the quarter with $7.16B in cash and short-term investments, a total debt of $36.27B, and net debt of $29.36B. Total assets were $106.68B, with equity of $37.64B. Financials further reflected stability, with operating cash flow of $13.01B, free cash flow of $9.14B, and capital expenditures of - $3.86B.

Price Forecast & Outlook

Our AI price prediction model suggests that Merck & Co., Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.71%, with price expected at $99.79 by January 05, 2026, within a range of $97.19 to $102.85 3-Month Outlook: Projected rise of 33.47%, reaching $139.77 by March 20, 2026, with a range of $136.57 to $143.22. 1-Year Outlook: Projected loss of -11.01%, with price at $93.19 by December 22, 2026, within a range of $89.31 to $98.14.

Key Takeaways

Merck & Co., Inc. (NYSE:MRK) shares are flat 5.27% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Merck & Co., Inc. trading at a premium to the broader market with a P/E of 13.7. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $117.04, suggesting 11.76% upside. Our AI forecast model points to short-term weakness (-4.71% over two weeks), a medium-term rise (33.47% over three months), and a longer-term loss (-11.01% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Merck & Co., Inc. (MRK) stock price?

Merck & Co., Inc. (NYSE: MRK) stock price is $105.08 in the last trading session. During the trading session, MRK stock reached the peak price of $105.39 while $104.33 was the lowest point it dropped to. The percentage change in MRK stock occurred in the recent session was 0.34% while the dollar amount for the price change in MRK stock was $0.36.

MRK's industry and sector of operation?

The NYSE listed MRK is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Merck & Co., Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MRK?

Lisa LeCointe-Cephas
Senior Vice President and Chief Ethics & Compliance Officer
Mr. Kenneth C. Frazier
Executive Chairman
Ms. Cristal N. Downing
Executive Vice President and Chief Communications & Public Affairs Officer
Ms. Caroline Litchfield
Executive Vice President & Chief Financial Officer
Ms. Jennifer L. Zachary
Executive Vice President & Gen. Counsel
Mr. Richard R. DeLuca Jr.
Executive Vice President & Pres of Merck Animal Health
Mr. Robert M. Davis J.D.
Chairman, Pres & Chief Executive Officer
Mr. Peter Dannenbaum
Vice President of Investor Relations
Mr. Steven C. Mizell
Executive Vice President & Chief HR Officer
Mr. Chirfi Guindo
Senior Vice President & Chief Marketing Officer for Merck Human Health
Mr. David Michael Williams
Executive Vice President and Chief Information & Digital Officer
Dr. Dean Y. Li M.D., Ph.D.
Executive Vice President & Pres of Merck Research Laboratories
Ms. Jennifer Mauer
Head of Global Communications & Corporation Brand

How MRK did perform over past 52-week?

MRK's closing price is 42.84% higher than its 52-week low of $73.31 where as its distance from 52-week high of $105.84 is -1.06%.

How many employees does MRK have?

Number of MRK employees currently stands at 73,000.

Link for MRK official website?

Official Website of MRK is: https://www.merck.com

How do I contact MRK?

MRK could be contacted at phone 908 740 4000 and can also be accessed through its website. MRK operates from 2000 Galloping Hill Road, Rahway, NJ 07033, United States.

How many shares of MRK are traded daily?

MRK stock volume for the day was 9.58M shares. The average number of MRK shares traded daily for last 3 months was 14.1M.

What is the market cap of MRK currently?

The market value of MRK currently stands at $264.09B with its latest stock price at $105.08 and 2.51B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	73000
Beta	0.3
Sales or Revenue	$59.87B
5Y Sales Change%	0.413%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

MRK Company Profile and Key Details

Merck & Co

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Valuation Metrics

Price Forecast & Outlook

Key Takeaways